News

OncoMed has been informed by the participating clinical sites of recent on-target mild-to-moderate bone-related adverse events for the two programs. To date, bone-related adverse events have been observed

The registry is part of Merck’s new global research initiative evaluating outcomes of patients with type 2 diabetes in everyday clinical practice. The research initiative and the new

Data from the Phase 2 study is being presented during the 19th Annual European Hematology Association (EHA) meeting being held in Milan, Italy. The poster presentation includes data

The alliance will initially focus on two key priorities: the development of drug-device combinations and delivery of care management services to improve adherence, simplify insulin treatment, and help

This result represents the largest settlement of a pharmaceutical case ever for several of the involved states, and a much higher settlement for each individual state than what

In February 2013, both the firms have voluntarily recalled all lots of Omontys and suspended promotional activities in the US after postmarketing reports of serious hypersensitivity reactions including

About 93 subjects at 38 centres in 14 countries were enrolled in PETIT2, a 2-part, double-blind, randomised placebo-controlled and open-label trial, which was designed to investigate the efficacy,

The tablets, a combination of 100mg aspirin and 15mg lansoprazole, are the first FDC drug in Japan to combine low-dose aspirin with a proton pump inhibitor. The company

Rilpivirine is a non-nucleoside reverse transcriptase inhibitor and is currently being marketed as Edurant, while dolutegravir is an integrase inhibitor marketed as Tivicay. If successfully developed and approved